Long-Term Administration of LL-37 Can Induce Irreversible Rosacea-like Lesion.
LL-37
inflammation
lesion
model
rosacea
skin fibrosis
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
24 Mar 2023
24 Mar 2023
Historique:
received:
20
02
2023
revised:
18
03
2023
accepted:
22
03
2023
medline:
15
5
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Rosacea is a chronic inflammatory skin disease whose late manifestations have not yet been clearly reported in animal models. The objective of this study is to describe the skin lesions and major histopathological changes in a rosacea-like phenotype in mice induced by prolonged LL-37 administration and furthermore, to assess the potential of long-term LL-37 administration in inducing irreversible rosacea-like skin lesion models. Balb/c mice were continuously injected intradermally with LL-37 every 12 h to induce a rosacea-like phenotype. After LL-37 injections were administered for 20 consecutive days, the area of rosacea-like lesions gradually expanded in the first 13 days, then entered a stable phase. Haematoxylin and eosin (H&E) and Van Gieson's staining showed a high degree of inflammatory cell aggregation, thickening of the epidermis and dermis, and collagen deposition in large quantities. The results of immunofluorescence staining and Western blotting showed that the expression of α-SMA, TNF-α, vimentin, and COL1 in the skin of mice was significantly upregulated. Short-term LL-37 administration induced rosacea-like lesions that only featured the aggregation of inflammatory factors and thickening of the epidermis, whereas no collagen hyperplasia was observed, and a full recovery was noticed. However, rosacea-like skin lesions induced by long-term LL-37 administration did not completely recover. Our study compares rosacea-like lesions induced by short-term versus long-term LL-37 administration, and the results suggest that irreversible rosacea-like lesions can be induced by long-term LL-37 administration.
Identifiants
pubmed: 37185701
pii: cimb45040177
doi: 10.3390/cimb45040177
pmc: PMC10136735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2703-2716Subventions
Organisme : National Natural Science Foundation of China
ID : No. 82204006
Organisme : National Natural Science Foundation of Hebei Province
ID : H2020209039
Organisme : Science and Technology Project of Hebei Education Department
ID : No. QN2022170
Organisme : Technology Project of Tangshan
ID : No. 21130208c
Organisme : Non-profit Central Re-search Institute Fund of Chinese Academy of Medical Sci-ence
ID : 2020-PT320-005
Organisme : Project of Key Laboratory of Functional and Clinical Translational Medicine
ID : XMMC-FCTM202202
Références
J Dermatol Sci. 2019 Jan;93(1):58-64
pubmed: 30658871
Drug Des Devel Ther. 2022 Dec 02;16:4127-4138
pubmed: 36483458
Front Immunol. 2021 Jul 12;12:609615
pubmed: 34322115
J Invest Dermatol. 2021 Dec;141(12):2780-2782
pubmed: 34565561
J Am Acad Dermatol. 2014 Nov;71(5):973-80
pubmed: 24993600
Biomed Pharmacother. 2019 Sep;117:109181
pubmed: 31387196
Int J Mol Sci. 2021 Oct 22;22(21):
pubmed: 34768832
J Invest Dermatol. 2021 Dec;141(12):2885-2894.e5
pubmed: 33745908
F1000Res. 2018 Dec 3;7:
pubmed: 30631431
Peptides. 2011 Jul;32(7):1469-76
pubmed: 21693141
Front Immunol. 2019 Apr 24;10:857
pubmed: 31068939
Biochem J. 2014 Jan 15;457(2):263-75
pubmed: 24117320
Microsc Res Tech. 2000 Aug 1;50(3):184-95
pubmed: 10891884
J Cosmet Dermatol. 2022 Mar;21(3):905-909
pubmed: 33872453
Int Immunopharmacol. 2020 Feb;79:106178
pubmed: 31918061
Int J Mol Sci. 2021 Jan 19;22(2):
pubmed: 33477764
Front Bioeng Biotechnol. 2021 May 03;9:638494
pubmed: 34012955
J Cell Mol Med. 2021 Dec;25(24):11290-11299
pubmed: 34783198
J Transl Autoimmun. 2019 Dec 17;3:100029
pubmed: 32743514
Surg Infect (Larchmt). 2018 Nov/Dec;19(8):804-811
pubmed: 30265592
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166563
pubmed: 36174876
Dermatoendocrinol. 2017 Oct 4;9(1):e1361574
pubmed: 29484096
Nat Med. 2007 Aug;13(8):975-80
pubmed: 17676051
Biomolecules. 2021 Aug 19;11(8):
pubmed: 34439906
J Am Acad Dermatol. 2020 Jun;82(6):1501-1510
pubmed: 32035944
J Invest Dermatol. 2021 Apr;141(4):800-809
pubmed: 32941918
Photodermatol Photoimmunol Photomed. 2010 Aug;26(4):198-204
pubmed: 20626822
J Am Acad Dermatol. 2019 Jun;80(6):1722-1729.e7
pubmed: 30240779
Int J Dermatol. 2020 Jun;59(6):e175-e182
pubmed: 31880327
Am J Clin Dermatol. 2021 Jul;22(4):457-465
pubmed: 33759078
Biomed Pharmacother. 2023 Jan;157:114091
pubmed: 36481403
Exp Dermatol. 2017 Nov;26(11):1143-1145
pubmed: 28500634
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769122
Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):15-25
pubmed: 20049649
Exp Ther Med. 2022 Aug 08;24(4):618
pubmed: 36177392
Skin Therapy Lett. 2021 Jul;26(4):1-8
pubmed: 34347259